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Background: The co-inhibitory receptor PD-1 is expressed in many tumors including
head and neck squamous cell carcinoma (HNSCC) and is an important immunotherapy
target. However, the role of PD-1 ligands, PD-L1, and particularly PD-L2, in the
tumor-stromal cell interactions that cause a tumor-permissive environment in HNSCC
is not completely understood and is the focus of our study.
Methods: Expression of PD-L1 and PD-L2 was analyzed by immunohistochemistry
in situ in HNSCC tumor tissue. Co-cultures were established between stromal
cells (fibroblasts and macrophages) and human papilloma virus (HPV)-positive and
HPV-negative HNSCC cell lines (HNSCCs) and PD-1 ligands expression was analyzed
using flow cytometry.
Results: PD-L1 and PD-L2 were expressed both in tumor cells and stroma in HNSCC
tissue in situ. In vitro, basal expression of PD-L1 and PD-L2 was low in HNSCCs and
high on fibroblasts and macrophages. Interestingly, HPV-positive but not HPV-negative
HNSCCs increased the expression of both PD-1 ligands on fibroblasts upon co-culture.
This effect was not observed with macrophages. Conversely, both fibroblasts and
macrophages increased PD-1 ligands on HPV-positive HNSCCs, whilst this was not
observed in HPV-negative HNSCCs. Crucially, we demonstrate that up-regulation of
PD-L1 and PD-L2 on fibroblasts by HPV-positive HNSCCs is mediated via TLR9.
Conclusions: This work demonstrates in an in vitro model that HPV-positive HNSCCs
regulate PD-L1/2 expression on fibroblasts via TLR9. This may open novel avenues to
modulate immune checkpoint regulator PD-1 and its ligands by targeting TLR9.
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INTRODUCTION
Advanced stage head and neck squamous cell
carcinoma (HNSCC) is treated with a combination of surgery,
radiotherapy, and chemotherapy with considerable morbidity
and mortality. A significant advance in knowledge was the
discovery that the oncogenic human papilloma virus (HPV,
subtypes 16 and 18) associates with 60–70% of oro-pharyngeal
cancer, a common HNSCC (1). Additionally, the observation
that HPV-positive HNSCC patients have a better prognosis
than those with HPV-negative HNSCC raises interesting
questions about the immune response to the HPV-antigen in
HPV-positive HNSCC.
Circulating T cells specific for HPV with anti-tumor activity
have been identified in patients with HNSCC by us and
others (2, 3), indicating an immune response to HPV virus.
However, HNSCC develops and progresses in spite of this
because tumor antigen-specific T cells fail to eliminate the
tumor. We have previously shown that circulating HPV-antigen
specific CD8+ T cells in patients with p16-positive HNSCC
express high levels of the co-inhibitory receptor programmed
cell death-1 (PD-1) (3), which may compromise their cytotoxic
function (4). PD-1 is expressed by activated T cells following
antigen encounter and it limits the proliferation and cytokine
production of effector T cells (5, 6). The inhibitory actions
of PD-1 are triggered by interaction with its ligands, PD-1
ligand 1 (PD-L1, B7-H1, or CD274), and PD-L2 (B7-DC or
CD273). These ligands compete for binding to PD-1 and their
expression pattern is complex. PD-L1 is constitutively expressed
by immune cells (T cells, B cells, dendritic cells, macrophages)
and also by non-haematopoietic parenchymal cells in many
tissues (7). In contrast, PD-L2 expression is reportedly restricted
to antigen presenting cells (dendritic cells, macrophages, and B
cells) (7).
PD-L1 is also expressed in many tumors (8–12), and more
recently tumor PD-L2 expression has been described (13).
Some of the mechanisms proposed to drive expression of
PD-L1 in tumors include interferon-γ (IFN-γ) produced
by tumor infiltrating lymphocytes, genomic alterations,
and activation of oncogenic signaling pathways (14–20).
However, additional mechanisms are likely to exist. PD-
1/PD-L1 axis is a major immune checkpoint important in the
prognosis of several solid tumors (melanoma, hepatocellular
carcinoma, and more recently HNSCC) (21–24) and is being
clinically targeted for immunotherapy (25–29). Recent work on
antibodies targeting PD-1 in advanced melanoma has yielded
encouraging improvement in survival (28) and clinical trials
are currently investigating the efficacy of anti-PD-1 and anti-
PD-L1 monoclonal antibodies in recurrent and/or metastatic
HNSCC (30–32).
Stromal cells such as tumor-associated macrophages
and fibroblasts have important roles in generating an
immunosuppressive tumor milieu (33). The role of PD-L1
and in particular PD-L2 in the tumor-permissive function of
stromal cells in HPV-positive and HPV-negative HNSCC is yet to
be completely understood. In this study we investigate whether
interactions between tumor and stromal cells influence the
TABLE 1 | Demographic characteristics of head and neck cancer patients.
Patient Age Gender Tumor site TNM p16
P1 61 F Tonsil T1N2bM0 Positive
P2 72 M Tonsil/BOT T4N2bM0 Positive
P3 62 M Tonsil T1N2aM0 Positive
P4 60 M Tonsil T3N0M0 Positive
P5 50 M PFS/PCA T4N0M0 Positive
P6 49 F Uvula T1N0M0 Negative
P7 83 M PFS/PCA T4N0M0 Negative
P8 50 F BOT T4N2cM0 Negative
P9 60 M Tonsil/BOT T4N2bM0 Negative
BOT, base of tongue; PCA, postcricoid area; PFS, pyriform sinus.
expression of PD-1 ligands in HNSCC.We demonstrate that PD-
L1 and PD-L2 are expressed in both tumor and stromal cells in
HNSCC tissue from treatment-naïve patients. We present novel
data that HPV-positive but not HPV-negative HNSCC cell lines
(HNSCCs) increase PD-L1 and PD-L2 expression on fibroblasts.
Of note, we demonstrate that the up-regulation of PD-L1
and PD-L2 on fibroblasts driven by HPV-positive HNSCCs is
mediated via TLR9 as it was abrogated by the TLR9-specific
antagonist ODN TTAGGG. Interestingly, chloroquine—
an endosomal TLR inhibitor—selectively abrogated PD-L2
up-regulation. This is the first report demonstrating TLR9
involvement in regulation of PD-L1 and PD-L2 expression in the
interaction between HPV-positive HNSCCs and stromal cells.
Our findings have potential implications for PD-1/PD-L1/PD-L2
immune checkpoint modulation in HPV-positive HNSCC by
unveiling TLR9 as an alternative target.
MATERIALS AND METHODS
HNSCC Tissue Samples
Immunohistochemistry was performed on tumor biopsies from
nine treatment-naive HNSCC patients with newly diagnosed
cancers. Patients’ characteristics are summarized in Table 1.
To reduce the impact of inflammatory comorbidities on the
expression of PD-1 and its ligands, strict exclusion criteria were
applied and patients with co-existing inflammatory disorders
such as autoimmune diseases, diabetes, renal failure, and cardiac
disease were excluded from the study. The study was carried out
in accordance with the recommendations of the Research Ethics
Committee London-Chelsea who approved the study; all study
subjects gave written informed consent in accordance with the
Declaration of Helsinki.
Cell Lines
The human HNSCC lines UPCI-SCC-099 (SCC099) and UPCI-
SCC-154 (SCC154) were purchased from DSMZ (Braunschweig,
Germany). The SCC099 line wasHPV-negative while the SCC154
line was HPV-positive. HNSCCs were maintained in Dulbecco’s
modified Eagle medium (DMEM, Sigma, #D6546) supplemented
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with 100 U/ml penicillin, 100µg/ml streptomycin, 15mM L-
glutamine, 1 × non-essential amino acids and 10% heat-
inactivated fetal calf serum (FCS, Corning) (culture medium).
Primary human BJ fibroblasts (ATCC CRL-2522) were cultured
in culture medium without non-essential amino acids.
Primary Human Monocyte-Derived
Macrophage Differentiation
Peripheral blood mononuclear cells (PBMCs) were isolated from
healthy blood donors by density gradient centrifugation using
Histopaque (Sigma-Aldrich; #10771). Monocytes were isolated
by adherence to tissue culture-treated 12-well-plates by plating 3–
5× 106 PBMCs per well in Iscove’s modified Dulbecco’s medium
(IMDM, Sigma-Aldrich; #I3390) supplemented with 100 U/ml
penicillin, 100µg/ml streptomycin, 15mM L-glutamine and
5% heat-inactivated pooled human serum (Lonza; #14-490E).
Following incubation for 1 h at 37◦C non-adhering cells were
removed and culture medium was replaced. The culture
medium was exchanged after 3–4 days and monocytes were
differentiated into macrophages by 6–7 days culture at 37◦C.
Macrophage differentiation was routinely verified by staining
withmonoclonal antibodies against CD14 (APC; BD Biosciences;
#555399) and CD68 (FITC; #562117; BD Biosciences).
Co-cultures
1 × 105 BJ fibroblasts were co-cultured with SCC099 or SCC154
cell lines (HNSCCs) at 1:1 ratio in culture medium. Fibroblasts
or HNSCCs cultured alone were used as controls. Similar co-
cultures were set up between primary human macrophages
and HNSCCs. Briefly, the culture medium was removed from
differentiated macrophages and 1.5 × 105 SCC099 or SCC154
cells were added in culture medium. Macrophages or HNSCCs
cultured alone were used as controls. Co-cultures were incubated
for 48 h prior to analysis of PD-1 ligand expression by flow
cytometry. In addition to direct co-cultures, cells (HNSCC,
fibroblasts, or macrophages) were treated with conditioned
media and PD-L1/PD-L2 expression was assessed after 48 h
by flow cytometry. Conditioned media were prepared from
supernatants of confluent cultures of HNSCCs, fibroblasts
and macrophages filtered through 0.2µm pore membranes to
remove viable and apoptotic cells. Where indicated, cells were
cultured in the presence of ODN TTAGGG (3.9µM, InvivoGen;
#tlrl-ttag151), chloroquine (10µM, InvivoGen; #tlrl-chq) or
neutralizing antibodies against interferon-γ (IFN-γ, 5µg/ml,
R&D Systems; MAB285), tumor necrosis factor-α (TNF-α,
5µg/ml, R&D Systems; #MAB610) and CD81/TAPA-1 (5µg/ml,
Abcam; #ab35026).
Cell Line Authentication
UPCI-SCC-099 (SCC099) and UPCI-SCC-154 (SCC154)
HNSCC cell lines were received directly from DSMZ
(Braunschweig, Germany), which used short tandem repeat
(STR) DNA profiling for their authentication. Primary BJ human
fibroblasts were obtained from ATCC, which used STR profiling
for their characterization. SCCs and fibroblasts were passaged
for <3 months and therefore re-authentication was not required.
Immunohistochemistry
The following primary antibodies were used: mouse monoclonal
CD4 (#NCL-L-CD4-368); mouse monoclonal CD8 (#NCL-
L-CD8-4B11); mouse monoclonal CD68 (#NCL-L-CD68)
and mouse monoclonal CD163 (#NCL-L-CD163) (all from
Novocastra, Leica Biosystems); rabbit polyclonal anti-inducible
nitric oxide synthase (iNOS, Abcam; #ab3523); goat polyclonal
PD-1 (#AF1086); and goat polyclonal PD-L2 (#AF1224)
(both R&D Systems); and mouse monoclonal CD274 (PD-L1)
(Biolegend; #329702). Paraffin sections of tumor tissue were cut
at 4µm and heated for 45min at 60◦C prior to staining. Heat
antigen retrieval was carried out using Epitope Retrieval Solution
1 (for all antibodies except CD68), pH 6 or Epitope Retrieval
Solution 2 (CD68), pH 9 at 100◦C for 20 or 30min, according to
the antibody. Antibodies were diluted 1:50 (CD8, PD-1, PD-L1)
or 1:100 for the remaining antibodies, and incubated for 15min.
Negative controls used antibody diluent in place of primary
antibody. Visualization for mouse monoclonal antibodies was
carried out using the Bond Polymer Refine Detection kit, an
HRP-conjugated 3,3’-diaminobenzidine (DAB) detection system
(Leica Biosystems; #DS9800). Visualization for goat polyclonal
antibodies was by Bond Intense R kit, a Biotin/streptavidin
HRP-conjugated DAB detection system, supplied by Leica
Microsystems and secondary antibody biotinylated rabbit
anti-goat (Dako; #E0466). All immunohistochemistry staining
was carried out using Bond III Fully automated staining system
and associated reagents, supplied by Leica Microsystems. Images
were captured with a Hamamatsu Nanozoomer RS2.0 slide
scanner, equipped with an Olympus objective (20× and 40×
magnification) using the NDP.scan software. Images were
generated using the NDP.view 2 software.
Flow Cytometry Analysis
For detection of PD-L1 and PD-L2, fibroblasts and HNSCC
cell lines (HNSCCs) cultured alone or in co-culture were
detached by incubation with Trypsin/EDTA (Sigma-Aldrich)
at 37◦C, followed by washes in culture medium. Macrophages
and HNSCCs cultured alone or in co-culture were collected
by incubation in PBS containing 5mM EDTA and 0.2% w/v
bovine serum albumin for 15min on ice and gentle scraping.
Cells were washed several times in PBS with 2% FCS and
stained for surface expression of epithelial cell adhesion
molecule (EpCAM) (APC; R&D Systems; #FAB9601A) to
distinguish HNSCCs from fibroblasts and macrophages.
Additionally, cells were stained with PE-conjugated monoclonal
antibodies against PD-L1 (#12-5983-42) and PD-L2 (#12-
5888-42) (both eBioscience) or PE-conjugated isotype control
antibodies (BD Biosciences; #555749). Initial experiments for
detection of PD-L1 expression used a mouse anti-human-
PD-L1 antibody (Biolegend; #329702) followed by staining
with PE-conjugated goat anti-mouse antibody (Sigma-Aldrich;
P9287). For macrophage-HNSCCs co-cultures, 7-AAD (BD
Biosciences; #559925) was used to exclude dead cells from
the analysis. Samples were acquired on a FACSCalibur (BD
Biosciences) flow cytometer and data analysis was performed
using FlowJo software version 7. Mean fluorescence intensity
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FIGURE 1 | PD-L1, PD-L2, PD-1, CD8, and CD4 expression in p16-positive and p16-negative HNSCC. PD-L1, PD-L2, PD-1, CD8, and CD4 expression was
assessed in tumor biopsy tissue from five p16-positive and four p16-negative HNSCC patients using immuno-histochemistry (details in Methods). Representative
staining (scale bars, 100µm) and cumulative data of marker expression (grading scale PD-L1/PD-L2: 1, low; 2, moderate; 3 high expression; grading scale PD-1,
CD8, CD4: 1, <50 cells/field; 2, 50–150 cells/field; 3, >150 cells/field).
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FIGURE 2 | CD68, CD163, and iNOS expression in p16-positive and p16-negative HNSCC. Macrophage marker expression was assessed in tumor biopsy tissue
from five p16-positive and four p16-negative HNSCC patients using immuno-histochemistry. Representative staining (scale bars, 100µm) and cumulative data of
marker expression (grading scale: 1, <50 cells/field; 2, 50–100 cells/field; 3, >100 cells/field).
(MFI) was calculated by subtracting the MFI of samples
stained with PE-conjugated isotype control from the MFI
of samples stained with PD-L1 and PD-L2, respectively.
MFI for samples indirectly stained with PD-L1/GAM-
PE was adjusted to match MFI of samples stained with
PE-conjugated PD-L1.
Quantification of Cytokines in
Culture Supernatants
Supernatants from co-cultures of fibroblasts and HPV-positive
HNSCCs were stored frozen until quantification of IFN-γ
and TNF-α by DuoSet ELISA (R&D Systems; #DY285, IFN-γ;
#DY210, TNF-α).
Statistical Analysis
One-way ANOVA with Bonferroni post-test for
multiple comparisons and unpaired two-tailed
Student’s t-test were performed using GraphPad
Prism assuming independent samples and normal
distribution (as indicated in the Figure legends).
Probability (p) values of < 0.05 were considered
statistically significant.
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FIGURE 3 | HPV-positive HNSCCs increase PD-L1 and PD-L2 on fibroblasts. PD-L1 and PD-L2 expression on primary BJ human fibroblasts, HPV-positive (SCC154),
and HPV-negative (SCC099) HNSCC cell lines (HNSCCs) was detected by flow cytometry. Illustrative histograms show PD-L1 and PD-L2 expression on fibroblasts
(black histograms), HPV-positive (red histograms), or HPV-negative (blue histograms) HNSCCs (A). Graphs show PD-L1 and PD-L2 expression (mean ± SEM; n = 5)
in fibroblasts, HPV-positive, and HPV-negative HNSCCs (B). Fibroblasts were cultured alone or co-cultured in direct contact (direct) with HPV-positive (SCC154) or
HPV-negative (SCC099) HNSCCs. Fibroblasts were identified in co-cultures by lack of EpCAM expression. Illustrative histograms show PD-L1 and PD-L2 expression
on fibroblasts cultured alone (black histograms) or co-cultured directly with HPV-positive SCC154 (C; red histograms) or HPV-negative SCC099 (D; blue histograms).
Graphs show PD-L1 and PD-L2 expression (mean ± SEM; n = 5) on fibroblasts cultured alone (w/o) or co-cultured directly with HNSCC cells (E). HPV-positive
(Continued)
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FIGURE 3 | (SCC154) or HPV-negative (SCC099) HNSCCs were cultured alone or co-cultured in direct contact (direct) with fibroblasts. HNSCCs were identified in
co-cultures by EpCAM expression. Illustrative histograms show PD-L1 and PD-L2 expression on HPV-positive SCC154 cultured alone (black histograms)
or co-cultured directly with fibroblasts (F; red histograms). Graphs show PD-L1 and PD-L2 expression (mean ± SEM; n = 4) on HPV-positive SCC154 cultured alone
or co-cultured directly with fibroblasts (G). Illustrative histograms show PD-L1 and PD-L2 expression on HPV-negative SCC099 cultured alone (black histograms) or
co-cultured directly with fibroblasts (H; blue histograms). Graphs show PD-L1 and PD-L2 expression (mean ± SEM; n = 4) on HPV-negative SCC099 cultured alone or
co-cultured directly with fibroblasts (I). *p < 0.05; **p < 0.01; ****p < 0.0001; ns, not significant (one-way ANOVA with Bonferroni correction for multiple comparisons)
Numbers adjacent to plots represent MFI values; dashed histograms show control staining with isotype-matched antibodies. MFI, mean fluorescence intensity.
RESULTS
PD-L1 and PD-L2 Are Expressed Both in
Tumor Cells and Stroma in HNSCC Tissue
We examined expression of PD-L1 and PD-L2 in nine
treatment-naïve HNSCC tumor tissue samples using
immunohistochemistry (clinical details in Table 1). PD-L1
was expressed in all tissue samples and was present both in
tumor cells and stromal tissue (Figure 1). Similarly, PD-L2
was also present in all tissue samples examined and both
tumor cells and stroma expressed PD-L2 in situ (Figure 1).
Semi-quantitative analysis did not reveal differences in
the expression of PD-1 ligands in p16-positive and p16-
negative HNSCC tissue (Figure 1). We next examined PD-1
expression in the HNSCC tissue. An infiltrate of PD-1+
cells was noted in all HNSCC samples (Figure 1). Moreover,
all HNSCC samples also exhibited CD8+ cell infiltration
(Figure 1). Fewer PD-1+ and CD8+ cells were present
in p16-negative samples (Figure 1). Compared to CD8
expression, relatively lower numbers of CD4+ cells were
found in HNSCC tumor tissue (Figure 1). We also examined
macrophage presence in HNSCC tumor tissue using CD68
(pan-macrophage marker), iNOS (M1 marker) and CD163
(M2 marker). CD68+ and CD163+ macrophages were noted
in all HNSCC, while iNOS-positive macrophages were not
identified (Figure 2).
HPV-Positive HNSCCs Up-Regulate PD-L1
and PD-L2 Expression on Fibroblasts
As we found that PD-1 ligands were expressed in both tumor
and stroma of HNSCC tissues, we examined if interaction
between HNSCC tumor cells and fibroblasts could influence
expression of PD-1 ligands. We therefore, tested the effect of
HPV-positive (SCC154) and HPV-negative (SCC099) HNSCC
cell lines (HNSCCs) on PD-1 ligand expression on BJ fibroblasts
in an in vitro co-culture system. Fibroblasts expressed high
baseline levels of PD-L1 and PD-L2, whilst HPV-positive and
HPV-negative HNSCCs expressed low levels (Figures 3A,B).
Interestingly, expression of PD-L1 on fibroblasts increased
significantly upon co-culture with HPV-positive HNSCCs
(Figures 3C,E, p < 0.0001). In contrast, HPV-negative HNSCCs
decreased PD-L1 on fibroblasts (Figures 3D,E). The same pattern
was noted for PD-L2 expression on fibroblasts: HPV-positive
HNSCCs significantly increased PD-L2 levels (Figures 3C,E,
p < 0.0001), whilst HPV-negative HNSCCs decreased PD-
L2 (Figures 3D,E).
Fibroblasts Up-Regulate PD-L1 and PD-L2
Expression in HPV-Positive HNSCCs
As HPV-positive HNSCCs up-regulated PD-1 ligands on BJ
fibroblasts, we also examined whether fibroblasts had a reciprocal
effect on PD-1 ligands expression on HNSCCs. Interaction with
fibroblasts in co-culture significantly increased PD-L1 and PD-
L2 expression on HPV-positive HNSCCs (Figures 3F,G, p <
0.0001). In contrast, PD-L1 and PD-L2 expression on HPV-
negative HNSCCs did not change following co-culture with
fibroblasts (Figures 3H,I).
Macrophages Up-Regulate PD-L1 and
PD-L2 on HPV-Positive HNSCCs
Macrophages are another important constituent of tumor stroma
and therefore, we tested the effect of HNSCCs on PD-1 ligand
expression bymacrophages. Primary peripheral bloodmonocyte-
derived human macrophages expressed both PD-L1 and PD-
L2 (Figure 4A). In contrast to our findings on fibroblasts, co-
culture with HPV-positive HNSCCs did not increase PD-L1 and
PD-L2 expression on macrophages (Figures 4B,D). Similarly,
HPV-negative HNSCCs did not affect PD-1 ligands expression
on macrophages (Figures 4C,D). We also examined the effect
of macrophages on PD-1 ligand expression by HNSCCs. PD-
L1 and PD-L2 expression on HPV-positive HNSCCs increased
significantly following direct co-culture with macrophages
(Figures 4E,F), although the effect was more marked for PD-
L1 than for PD-L2. In contrast, macrophages did not alter PD-1
ligands expression on HPV-negative HNSCCs (Figures 4G,H).
Conditioned Medium From HPV-Positive
HNSCCs Up-Regulates PD-L1 and PD-L2
on Fibroblasts
We next analyzed the mechanisms underlying the up-regulation
of PD-1 ligands on fibroblasts upon co-culture withHPV-positive
HNSCCs. To determine whether this was contact dependent
or mediated via soluble factors, fibroblasts were cultured either
with HPV-positive HNSCCs or with conditioned medium
(supernatant) from these cells (details in Methods). Treatment
with conditioned medium induced significant PD-L1 up-
regulation on fibroblasts (Figures 5A,B). However, the effect of
conditioned medium was smaller than that observed with direct
co-culture: whilst direct co-culture with HPV-positive HNSCCs
resulted in four-fold up-regulation of PD-L1, conditioned
medium induced a 1.6 fold increase (Figures 5A,B). Next we
analyzed the effect of conditioned medium on PD-L2 expression.
Significant up-regulation of PD-L2 was observed on fibroblasts
cultured with conditioned medium from HPV-positive HNSCCs
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FIGURE 4 | PD-L1 and PD-L2 expression in co-cultures of macrophages and HPV-positive or HPV-negative HNSCCs. Macrophages were cultured alone (w/o) or
co-cultured in direct contact (direct) with HPV-positive (SCC154) or HPV-negative (SCC099) HNSCC cell lines (HNSCCs). Illustrative histograms show PD-L1 and
PD-L2 expression on macrophages cultured alone (A; black histograms). Macrophages were identified in co-cultures by lack of EpCAM expression. Illustrative
histograms show PD-L1 and PD-L2 expression on macrophages cultured alone (black histograms) or co-cultured directly with HPV-positive SCC154 (B; red
histograms) or HPV-negative SCC099 (C; blue histograms). Graphs show PD-L1 and PD-L2 expression (mean ± SEM; n = 4) on macrophages cultured alone (w/o)
or co-cultured directly with HNSCCs (D). HPV-positive (SCC154) or HPV-negative (SCC099) HNSCCs were cultured alone or co-cultured in direct contact (direct) with
macrophages. HNSCCs were identified in co-cultures by EpCAM expression. Illustrative histograms show PD-L1 and PD-L2 expression on HPV-positive SCC154
cultured alone (black histograms) or co-cultured directly with macrophages (E; red histograms). Graphs show PD-L1 and PD-L2 expression (mean ± SEM; n = 3) on
HPV-positive SCC154 cultured alone or co-cultured directly with macrophages (F). Illustrative histograms show PD-L1 and PD-L2 expression on HPV-negative
SCC099 cultured alone (black histograms) or co-cultured directly with macrophages (G; blue histograms). Graphs show PD-L1 and PD-L2 expression (mean ± SEM;
n = 3) on HPV-negative SCC099 cultured alone or co-cultured directly with macrophages (H). *p < 0.05; **p < 0.01; ns, not significant (D: one-way ANOVA with
Bonferroni correction for multiple comparisons; F,H: unpaired two-tailed Student’s t-test) Numbers adjacent to plots represent MFI values; dashed histograms show
control staining with isotype-matched antibodies. MFI, mean fluorescence intensity.
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FIGURE 5 | Conditioned medium from HPV-positive HNSCCs up-regulates PD-L1 and PD-L2 on fibroblasts. Fibroblasts were cultured alone or co-cultured in direct
contact with HPV-positive SCC154 (direct) or with conditioned medium from HPV-positive SCC154 (CM). Illustrative histograms show PD-L1 and PD-L2 expression
on fibroblasts cultured alone (black histograms) or co-cultured with conditioned medium from HPV-positive SCC154 (A; red histograms). Graphs show PD-L1 and
PD-L2 expression (mean ± SEM; n = 13) on fibroblasts cultured alone (w/o), co-cultured directly with HPV-positive SCC154 (direct) or with conditioned medium from
HPV-positive SCC154 (CM) (B). HPV-positive (SCC154) HNSCCs were cultured alone or co-cultured in direct contact with fibroblasts (Fibro direct) or with conditioned
medium from fibroblasts (Fibro CM). Illustrative histograms show PD-L1 and PD-L2 expression on HPV-positive SCC154 cultured alone (black histograms) or
co-cultured with conditioned medium from fibroblasts (C; red histograms). Graphs show PD-L1 and PD-L2 expression (mean ± SEM; n = 4) on HPV-positive
SCC154 cultured alone (w/o), co-cultured directly with fibroblasts (Fibro direct) or with conditioned medium from fibroblasts (Fibro CM) (D). Macrophages were
cultured alone (w/o) or co-cultured in direct contact with HPV-positive SCC154 (direct) or with conditioned medium from HPV-positive SCC154 (CM). Graphs show
PD-L1 and PD-L2 expression (mean ± SEM; n = 3) on macrophages for the indicated conditions (E). HPV-positive SCC154 HNSCCs were cultured alone (w/o) or
co-cultured in direct contact with macrophages (MFs direct) or with conditioned medium from macrophages (MFs CM). Graphs show PD-L1 and PD-L2 expression
(mean ± SEM; n = 2) on HPV-positive SCC154 HNSCCs for the indicated conditions (F). **p < 0.01; ****p < 0.0001; ns, not significant (one-way ANOVA with
Bonferroni correction for multiple comparisons) Numbers adjacent to plots represent MFI values; dashed histograms show control staining with isotype-matched
antibodies. MFI = mean fluorescence intensity.
(Figures 5A,B). Of note, the effect of conditioned medium on
PD-L2 expression on fibroblasts was similar to that induced
by direct co-culture with HPV-positive HNSCCs. As fibroblasts
increased PD-1 ligand expression on HPV-positive HNSCCs in
co-culture (Figures 3F,G), we tested whether this was also the
case with conditioned medium from fibroblasts. Conditioned
medium from cultures of fibroblasts did not alter PD-L1 and PD-
L2 ligand expression on HPV-positive HNSCCs (Figures 5C,D).
We also assessed the effect of HPV-positive HNSCCs conditioned
medium on macrophages and found no change on PD-L1 and
PD-L2 expression (Figure 5E). Similarly, conditioned medium
frommacrophages had no effect on PD-L1 and PD-L2 expression
on HPV-positive HNSCCs (Figure 5F).
The Up-Regulation of PD-1 Ligands on
Fibroblasts Induced by HPV-Positive
HNSCCs Is Not Mediated by Interferon-γ
(IFN-γ), Tumor Necrosis Factor-α (TNF-α),
or Tetraspanin CD81
Inflammatory cytokines such as IFN-γ have been proposed
to mediate PD-L1 up-regulation on several cell types
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FIGURE 6 | Blockade of IFN-γ, TNF-α, or CD81 does not affect PD-L1 and PD-L2 up-regulation by HPV-positive HNSCCs. Fibroblasts were cultured alone (w/o) or
co-cultured in direct contact with HPV-positive SCC154 (SCC154 direct) or with conditioned medium from HPV-positive SCC154 (SCC154CM) as indicated. Graphs
(A) show IFN-γ and TNF-α levels in culture supernatants (mean ± SEM; n = 4). The dashed red line indicates the lowest value (15.6 pg/ml) of the dynamic range for
(Continued)
Frontiers in Immunology | www.frontiersin.org 10 July 2019 | Volume 10 | Article 1644
Baruah et al. TLR9 and PD-1/PD-L1/PD-L2 Pathways in HNSCC
FIGURE 6 | the ELISA assays used. Neutralizing antibodies anti-IFN-γ (B,C), anti-TNF-α (D,E), or anti-CD81 (F,G) were added to the cultures as indicated. Illustrative
histograms show PD-L1 and PD-L2 expression on fibroblasts cultured alone (black histograms), co-cultured directly with HPV-positive SCC154 or with conditioned
medium from HPV-positive SCC154 alone (red histograms) or in the presence of blocking antibodies (green histograms). Graphs show PD-L1 and PD-L2 expression
(mean ± SEM; n = 3) on fibroblasts for the indicated treatments. ns, not significant (one-way ANOVA with Bonferroni correction for multiple comparisons) Numbers
adjacent to plots represent MFI values; dashed histograms show control staining with isotype-matched antibodies. MFI, mean fluorescence intensity.
(19, 20). Moreover, tumor-infiltrating lymphocytes were
proposed to induce PD-L1 expression in HNSCC via IFN-γ (23).
We therefore tested supernatants from fibroblasts co-cultured
with HPV-positive HNSCCs or with conditioned medium from
these cells for inflammatory cytokines. No IFN-γ or TNF-α
was present in supernatants from fibroblasts cultured alone
or in the presence of HPV-positive HNSCCs or conditioned
medium from these cells (Figure 6A). In addition, blocking
IFN-γ or TNF-α with neutralizing antibodies did not have
any impact on PD-L1 and PD-L2 up-regulation on fibroblasts
cultured with HPV-positive HNSCCs or conditioned medium
(Figures 6B–E). We also investigated whether transfer of PD-1
ligands via microvesicles derived from HPV-positive HNSCCs
could account for PD-L1 and PD-L2 increase on fibroblasts.
We therefore targeted tetraspanin CD81 (TAPA-1), which is a
common component of tetraspanin-enriched microdomains
in the membrane of microvesicles and has been implicated in
the entry of viruses like HPV and hepatitis C virus in epithelial
cells (34). Blocking antibodies against tetraspanin CD81 did
not inhibit PD-L1 and PD-L2 up-regulation by fibroblasts co-
cultured with HPV-positive HNSCCs or conditioned medium
from these cells (Figures 6F,G).
The Up-Regulation of PD-L1 and PD-L2 on
Fibroblasts by HPV-Positive HNSCCs Is
Mediated via Toll-Like Receptor-9 (TLR9)
Toll-like receptors (TLR) have been implicated in up-regulation
of PD-L1 in antigen presenting cells (35). Endosomal TLR9 is
a primary sensor for bacterial and viral DNA (36). As HPV
is a double stranded DNA virus we next investigated whether
TLR9 was involved in PD-L1 and PD-L2 expression by fibroblasts
co-cultured with HPV-positive HNSCCs. For this purpose we
used the oligonucleotide ODN TTAGGG (A151), which is a
specific antagonist of human TLR9 (37, 38). Notably, ODN
TTAGGG abrogated the up-regulation of both PD-L1 and
PD-L2 in fibroblasts co-cultured with HPV-positive HNSCCs
(Figures 7A,C), whilst it had no effect on the baseline expression
of PD-1 ligands on fibroblasts (Figures 7D,E). Furthermore,
ODN TTAGGG significantly inhibited the up-regulation of PD-
L1 and PD-L2 in fibroblasts cultured with conditioned medium
from HPV-positive HNSCCs (Figures 7B,C). As fibroblasts
increased the expression of PD-1 ligands on HPV-positive
HNSCCs (Figures 3F,G), we tested whether this effect was also
mediated by TLR9. Indeed, ODN TTAGGG hindered the up-
regulation of PD-L1 and PD-L2 on HPV-positive HNSCCs
cultured with fibroblasts (Figures 7F,G). In addition to ODN
TTAGGG, we tested another TLR9 inhibitor, chloroquine, which
works by blocking endosomal acidification that is required
for optimal TLR9 activation, and by inhibiting the binding of
DNA to TLR9 (39, 40). As observed with ODN TTAGGG,
chloroquine inhibited the up-regulation of PD-L2 by fibroblasts
cultured either directly with HPV-positive HNSCCs or with
conditionedmedium from these cells (Figures 7H–J). In contrast
to ODN TTAGGG, chloroquine did not affect PD-L1 expression
on fibroblasts in these experiments (Figures 7H–J). Moreover,
chloroquine had no effect on the baseline expression of PD-
L1 and PD-L2 by fibroblasts (Figures 7K,L). In contrast to
ODN TTAGGG, chloroquine also did not affect the fibroblast-
induced up-regulation of PD-L1 and PD-L2 on HPV-positive
HNSCCs (Figures 7M,N).
DISCUSSION
This work investigated the role of the inhibitory PD-1
pathway with focus on PD-L1 and PD-L2 in the stromal
microenvironment in HNSCC. Here we show that PD-L1 and
PD-L2 are expressed in both tumor cells and stroma in situ
in treatment-naïve primary HSNCC. Of note, we demonstrate
that HPV-positive but not HPV-negative HNSCC cell lines
(HNSCCs) up-regulate both PD-L1 and PD-L2 expression on
fibroblasts in vitro via a TLR9-depedent mechanism. To the best
of our knowledge this is the first report identifying TLR9 as a new
regulator of PD-1 ligand expression in fibroblasts in the context
of tumor-stroma interaction. Our novel results suggest that
HPV-positive HNSCC enlist fibroblasts and generate a tumor-
permissive microenvironment via TLR9-mediated engagement
of PD-1/PD-L1/PD-L2 pathways.
PD-L1 and PD-L2 are members of the B7 superfamily of
co-stimulatory/co-inhibitory molecules (41) and bind to PD-1
expressed on T cells. In immune responses to tumors, PD-1
engagement on T cells is responsible for switching T lymphocytes
off and preventing robust anti–tumor activity (4). Thereby PD-1
ligands have pivotal roles in maintaining an immunosuppressive
microenvironment in tumors. In comparison to PD-L1, little
information is available on PD-L2 expression in HNSCC. We
show that both PD-1 ligands (PD-L1 and PD-L2) are expressed
in HNSCC tissue in situ and are present in both tumor
and stromal cells. Our findings on PD-L2 expression are in
agreement with a recent study on tissue expression of PD-
L2 from 40 HNSCC patients (13). This study also suggested
that PD-L2 expression is a significant predictor of clinical
response to pembrolizumab (an anti-PD-1 checkpoint inhibitor)
and progression-free survival, independent of PD-L1 status in
HNSCC (13). These data highlight a role for PD-L2 in HNSCC
and suggest that PD-L2, in addition to PD-L1, has a role in
tumor-stroma interactions in HNSCC in vivo. However, very
little is known about the mechanisms regulating PD-L1 and in
particular PD-L2 expression in HNSCC tumor and stroma.
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FIGURE 7 | The TLR9 antagonists ODN TTAGGG and chloroquine inhibit PD-1 ligands up-regulation on fibroblasts co-cultured with HPV-positive HNSCCs.
Fibroblasts were cultured alone (w/o) or co-cultured in direct contact with HPV-positive SCC154 (SCC154 direct) or with conditioned medium from HPV-positive
SCC154 (SCC154CM) in the presence or absence of the TLR9 antagonists ODN TTAGGG (ODN) or chloroquine (CHQ). Illustrative histograms show PD-L1 and
(Continued)
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FIGURE 7 | PD-L2 expression on fibroblasts cultured alone (black histograms), co-cultured directly with HPV-positive SCC154 (red histograms) or co-cultured directly
with HPV-positive SCC154 in the presence of ODN (A) or CHQ (H) (green histograms). Illustrative histograms show PD-L1 and PD-L2 expression on fibroblasts
cultured alone (black histograms), cultured with conditioned medium from HPV-positive SCC154 (red histograms) or with conditioned medium from HPV-positive
SCC154 in the presence of ODN (B) or CHQ (I) (green histograms). Graphs show PD-L1 and PD-L2 expression (mean ± SEM; n = 6) on fibroblasts for the indicated
treatments (C,J). Illustrative histograms show PD-L1 and PD-L2 expression on fibroblasts cultured alone (black histograms) or in the presence of ODN (D) or CHQ (K)
(green histograms). Graphs show PD-L1 and PD-L2 expression (mean ± SEM; n = 4) on fibroblasts for the indicated treatments (E,L). HPV-positive SCC154 were
cultured alone or co-cultured in direct contact (direct) with fibroblasts in the presence or absence of TLR9 inhibitor ODN TTAGGG (ODN) or chloroquine (CHQ).
Illustrative histograms show PD-L1 and PD-L2 expression on HPV-positive SCC154 cultured alone (black histograms), co-cultured directly with fibroblasts alone (red
histograms), or co-cultured directly with fibroblasts in the presence of ODN (F) or CHQ (M) (green histograms). Graphs show PD-L1 and PD-L2 expression (mean ±
SEM; n = 6) on HPV-positive SCC154 cultured alone or for the indicated co-culture conditions (G,N). *p < 0.05; **p < 0.01; ****p < 0.0001; ns, not significant
(one-way ANOVA with Bonferroni correction for multiple comparisons) Numbers adjacent to plots represent MFI values; dashed histograms show control staining with
isotype-matched antibodies. MFI, mean fluorescence intensity.
We found constitutive expression of PD-L1 and PD-L2
in human primary BJ fibroblasts. Expression of PD-L2 has
been previously described in fibroblasts from human intestinal
mucosa (42) and from human lung cancers (43), although
its role on fibroblasts is not completely understood. Notably,
we found that co-culture with the HPV-positive HNSCC cell
line (HNSCCs) significantly increased the expression of PD-
L1 and PD-L2 on fibroblasts. This effect of HPV-positive
HNSCCs was restricted to fibroblasts as it was not observed
on primary human macrophages. Of note, fibroblasts and
macrophages also increased the expression of PD-L1 and PD-
L2 on HPV-positive HNSCCs. These results suggest a bi-
directional interaction between HPV-positive tumor cells and
stromal cells, resulting in an overall up-regulation of both PD-L1
and PD-L2.
A novel facet of our work unveils TLR9 as a receptor
mediating the up-regulation of PD-L1 and PD-L2 on fibroblasts
following interaction with HPV-positive HNSCCs. We
found that ODN TTAGGG, a specific antagonist of TLR9,
abrogated the up-regulation of both PD-L1 and PD-L2.
Interestingly, chloroquine, another TLR9 inhibitor blocked
PD-L2 up-regulation but had no effect on PD-L1. These
findings may be explained by different mechanisms employed
by ODN TTAGGG and chloroquine in TLR9 inhibition.
TLR9 is an endosomal pattern recognition receptor for
unmethylated 2’-deoxyribo(cytidine-phosphate-guanosine)
(CpG) oligonucleotide (ODN) DNA motifs preferentially
found in bacterial and viral DNA and rare in mammalian cells
(36). ODN TTAGGG is believed to interfere with CpG ODN
colocalisation with TLR9 in endosomes (44), whilst chloroquine
hinders TLR9 activation by inhibiting endosomal acidification
and blocking nucleic acid binding to TLR9 (39, 40). The different
effects of ODN TTAGGG and chloroquine on PD-L1 and PD-L2
suggest further complexities in TLR9 regulation of PD-1 ligand
expression that warrant investigation. In contrast to the effect
on fibroblasts, HPV-positive HNSCCs did not up-regulate
PD-L1 or PD-L2 on monocyte-derived macrophages. This may
be due to low TLR9 expression in human monocyte-derived
macrophages (45, 46).
Our in vitro results show a clear influence of HPV status
on the expression of PD-L1 and PD-L2 by fibroblasts coming
into contact with HNSCC cell lines. This is in keeping with
in situ findings by Lyford-Pike et al. that PD-L1 expression
was more common in HPV-positive HNSCC tissue (70%, n =
14/20 of their cohort) compared to HPV-negative samples (29%,
n = 2/10) (23). In our study, immunohistochemistry staining
did not reveal differences in PD-L1 and PD-L2 expression in
treatment-naïve p16-positive compared to p16-negative HNSCC
tissue samples (Figure 1), which may be due to the smaller
sample size. Of note, a recent RNASeq gene expression profiling
in more than 500 treatment-naïve HNSCC tissue samples did
not identify differences in PD-L1 expression in HPV-positive
and HPV-negative HNSCC, even though IFN-γ (an inducer
of PD-L1) was significantly higher in the HPV-positive group
(47). It is possible that in the tumor microenvironment, up-
regulation of PD-1 ligands is influenced by multiple factors
in addition to HPV. Quantification of PD-1 ligands solely in
fibroblasts in tumor tissue in situ presents major challenges
as no specific markers are available that can reliably identify
fibroblasts in situ.
A limitation of our study is the use of an in vitro
co-culture system to dissect the effect of the interactions
between HNSCC cell lines and stromal cells on the expression
of PD-1 ligands. For ethical and feasibility reasons, the
fibroblasts used in this study were primary established cell
lines and macrophages were generated from peripheral blood
monocytes of normal donors. To investigate fibroblasts and
macrophages directly isolated from HNSCC tumor tissue is
challenging because of limited amounts of fresh tumor tissue
available for research. Moreover, methods used to isolate
macrophages and fibroblasts from tumor tissue and propagate
these cells in vitro alter the phenotype and function of
these cells.
Our results show that PD-1/PD-L1 and PD-1/PD-L2
pathways are important in the bidirectional interaction
between tumor cells and stromal cells in HNSCC and
could shape the anti-tumor immune response. We
propose TLR9 as a new regulator of the interaction
between HPV-positive HNSCCs and stromal cells,
specifically fibroblasts, which controls PD-L1 and PD-
L2 expression. Further dissection of TLR9’s role in
modulation of PD-1 ligands could reveal novel strategies
to target PD-1 pathways and improve clinical outcomes in
HPV-positive HNSCC.
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